Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.76 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | ATM | Q13315 | 2/20 | 0.73 |
| ▸ | PGR | P06401 | 2/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine SCHEMBL2348477 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL8173336 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL14031683 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29349776 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29374661 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL6353316 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL13753350 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7200287 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL679202 | 0.99 | RECQL (0.98) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7621246 | 0.99 | RECQL (0.98) | RECQLBLMESR1ADORA3INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 87611 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| CN-122029431-A | STK 1-based therapeutic stratification | 阿罗塞尔公司 | 2026-05-12 | — | — | CN | claimed |
| WO-1994020072-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 1994-09-15 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0351561-B1 | Novel esters of estramustine | KABI PHARMACIA AB (SE) | 1993-10-27 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| CN-1045792-A | The manufacture method of esters | PHARMACIA AB (SE) | 1990-10-03 | — | — | CN | claimed |
| EP-0351561-A1 | Novel esters of estramustine | Kabi Pharmacia AB (SE) | 1990-01-24 | — | — | EP | claimed |
| EP-0227593-A1 | Use of chelating agents | THE HOSPITAL FOR SICK CHILDREN (CA) | 1987-07-01 | — | — | EP | claimed |
| US-4592869-A | Selective acylation process | AKTIEBOLAGET LEO (SE) | 1986-06-03 | — | — | US | claimed |
| US-4584136-A | Process for preparing Estracyt compounds having a carcinostatic bound thereto | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1986-04-22 | — | — | US | claimed |
| EP-0138153-A2 | A selective acylation process | AB LEO (SE) | 1985-04-24 | — | — | EP | claimed |